An interventional study of Function-Friendly Semi-Fowler Positioning in Coronary Disease, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 224 studies in Coronary Disease with a site in China — 69 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.
Among the 224 studies in Coronary Disease with a site in China, this one is the 140th largest by planned enrollment of the 142 interventional ones that give a count, is one of 16 that started in 2026, is one of 87 with no phase, reaches primary completion later than 63 of the 77 other live ones, and was the 224th registered.
1,522 studies on the registry are indexed under Coronary Disease; 168 are open to participants now.
Browse Coronary Disease studies →69 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Gan Lijun · Sites in China
Ages 18+
Xia Liang · Sites in China
Ages 50–75
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
224 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 10 · Phase 4 34
First in 1999; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 220 across the 142 interventional studies, 1,508 across the 82 observational. Of the 75 that completed or were terminated, 11 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 224 have an industry lead sponsor. The 10 most frequent:
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Shanghai Zhongshan Hospital has 4 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Coronary Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT06472908Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEfficacy and Safety of Colchicine After PCI | 2027-06-30 |
| NCT07259278China National Center for Cardiovascular DiseasesIntelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients | 2026-11-30 |
| NCT07841275China Academy of Chinese Medical SciencesReal-World Effectiveness and Costs of Yiqi Fumai Lyophilized Injection in Coronary Heart Disease-Related Chronic Heart Failure | 2026-12 |
| NCT05397392Nanjing First Hospital, Nanjing Medical UniversityResearch on Optimal Diagnosis and Treatment of Cardiorenal Syndrome | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 224 studies in Coronary Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess whether planned coronary angiography (CAG), and simple percutaneous coronary intervention (PCI) when needed, can be completed safely and technically while participants are in a semi-sitting position with the head of the procedure table raised to 60 degrees. Ten clinically stable adults scheduled for an elective procedure are planned. The first stage will include participants undergoing CAG. After a safety review, the study may include participants expected to need only simple PCI. Heart rhythm, blood pressure, and blood oxygen will be monitored continuously. If predefined safety criteria occur, staff will lower the table or return the participant to a flat position and provide usual clinical care. Researchers will describe procedure completion, image quality, radiation exposure, contrast use, tolerance of the position, and safety events through 3 days after the procedure. This exploratory study is not designed to establish treatment efficacy.
This is a prospective, single-center, open-label, single-arm, staged early-feasibility study at Zhongshan Hospital, Fudan University. The planned enrollment is 10 participants aged 18 to 75 years. Eligible participants are clinically stable and scheduled for elective transradial CAG or planned simple PCI, and can tolerate a monitored 60-degree semi-Fowler position for at least 10 minutes before the procedure. The first stage prioritizes CAG. Participants expected to need only simple PCI may be enrolled only after a safety review confirms that the workflow is executable without unacceptable risk. During CAG and, when clinically indicated, simple PCI, the procedure table will be raised to a default head elevation of 60 degrees. ECG, blood pressure, and oxygen saturation will be monitored continuously. If chest pain, significant dyspnea, persistent oxygen saturation below 90%, systolic blood pressure below 90 mmHg or a decrease of at least 30% requiring intervention, sustained ventricular tachycardia or fibrillation, cerebral hypoperfusion, equipment collision, catheter or tubing traction, or another predefined safety concern occurs, the positioning intervention will stop and the table will be lowered or the participant returned to 0-degree supine; usual clinical care will take priority. CAG and PCI technical success will be described among participants undergoing the respective procedure. Safety events will be collected from the start of the positioning intervention through 3 days after the procedure. Other measures include image quality, completion of standard projections, fluoroscopy time, dose-area product, contrast volume, procedure duration, positioning changes, and tolerance. No investigational drug is used. The commercial angiography X-ray system is used as a carrier for the positioning intervention; the study does not modify or evaluate the device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive the same positioning intervention during elective transradial CAG and, if clinically indicated, simple PCI. The procedure table is raised to a default head elevation of 60 degrees, with continuous ECG, blood pressure, and oxygen saturation monitoring. If predefined safety concerns occur, the table angle is lowered or the participant is returned to 0-degree supine and usual clinical care is provided.
Other: Function-Friendly Semi-Fowler Positioning
The procedure table head is elevated to a default 60-degree semi-Fowler position during elective transradial coronary angiography and, if clinically indicated, simple PCI. ECG, blood pressure, and oxygen saturation are continuously monitored. If predefined safety criteria occur, the table angle is reduced or the participant is immediately returned to 0-degree supine and usual clinical care is provided. The commercial angiography X-ray system and adjustable procedure table are used as available clinical equipment; no device hardware, software, collision protection, interlocks, image processing, or dose-control functions are modified or evaluated.
Proportion of Participants With Coronary Angiography (CAG) Technical Success
The number of participants undergoing CAG who complete the planned CAG in the prespecified semi-Fowler position without position-related unplanned return to supine or substantial angle reduction, procedure discontinuation, access-site change, missing key projections, or participant/equipment collision, and whose images are independently confirmed to be diagnostic, divided by the number of participants undergoing CAG.
Time frame: During the CAG procedure
Proportion of Participants With Percutaneous Coronary Intervention (PCI) Technical Success
Among participants who undergo PCI, the proportion who complete planned device delivery, treatment, and withdrawal while meeting the protocol-defined positioning and safety requirements. PCI success is calculated using participants who undergo PCI as the denominator.
Time frame: During the PCI procedure
Participants With Position-Related Serious Adverse Events or Prespecified Safety Events
Number and proportion of participants experiencing a position-related serious adverse event or any prespecified safety event: hemodynamic instability, hypoxia, sustained arrhythmia, cerebral hypoperfusion, unplanned respiratory or circulatory support, mechanical collision, or emergency return to supine.
Time frame: From the start of the positioning intervention through 3 days after the procedure
Diagnostic Acceptability of Coronary Angiography Images
Coronary angiography and fluoroscopy image quality rated on a 1-to-3 Likert scale; a score of 2 or 3 is acceptable. Images are assessed by two independent physicians, with adjudication by a third if needed.
Time frame: During the procedure
Completion of Standard Coronary Angiographic Views and Visualization of Major Coronary Segments
Completion of standard left anterior oblique, right anterior oblique, cranial, and caudal projections, and the ability to visualize the left anterior descending, left circumflex, and right coronary arteries and their major branches.
Time frame: During the procedure
Total Fluoroscopy Time
Total fluoroscopy time recorded during the CAG and, if performed, PCI procedure.
Time frame: During the procedure
Dose-Area Product (DAP)
Dose-area product and other radiation dose parameters recorded by the angiography system.
Time frame: During the procedure
Contrast Volume
Total contrast-media volume administered during the procedure.
Time frame: During the procedure
Procedure Duration
Total duration of the CAG procedure and, if performed, PCI procedure, recorded as specified in the study CRF.
Time frame: During the procedure
Positioning Tolerance and Adjustments
Table-head angle, number and reasons for position adjustments, participant symptoms, unplanned return to 0-degree supine, and equipment collision events.
Time frame: During the procedure
Access and Device Delivery Completion
Successful radial artery access and completion of planned device delivery and withdrawal, as applicable to the procedure performed.
Time frame: During the procedure
Plan to share: Undecided — The protocol states that any data sharing must use de-identified data and receive the required approvals. Whether individual participant data will be shared, and the timing, access process, and supporting information, have not yet been determined.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.
Of 178 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 18 months is below that.
Counting every sponsor, half of 200 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.